Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04115254 · ClinicalTrials.gov registry record · NA
Stereotactic Magnetic Resonance Guided Radiation Therapy
A NA study of Prostate Cancer and Lung Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 397
- Enrollment target
- 2
- Study locations
NCT04115254: Recruiting NA study of Prostate Cancer and Lung Cancer, sponsored by Dana-Farber Cancer Institute.
NCT04115254 is a NA study of Prostate Cancer and Lung Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 397 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04115254, a NA study of Prostate Cancer and Lung Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 397 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures
Primary Outcome
Enrolling patients and delivering SMART on the MR Linac
Conditions Studied
Interventions
- RADIATION MR-guided Linac
Study Locations (2)
Massachusetts
- Brigham & Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2019-10-22 |
| Est. Completion | 2028-06 |
| Phase | NA |
What NCT04115254 shows while recruiting
NCT04115254 is an interventional study that assigns participants to a tested intervention. The registered 397 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (35% lower).
The record links to 10 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which MR-guided Linac is the first listed.
NCT04115254 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04115254 about?
NCT04115254 is a clinical study titled "Stereotactic Magnetic Resonance Guided Radiation Therapy". This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Ph...
What is the current status of trial NCT04115254?
This trial is currently recruiting. It is a NA study. The enrollment target is 397 participants. The study started on 2019-10-22. Estimated completion is 2028-06.
What conditions does trial NCT04115254 study?
This clinical trial studies the following conditions: Prostate Cancer, Lung Cancer, Pancreas Cancer, Mesothelioma, Renal Cancer.
What interventions are being tested in trial NCT04115254?
The interventions under investigation include: MR-guided Linac (RADIATION).
Who is sponsoring clinical trial NCT04115254?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04115254 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04115254's enrollment target sits among peer trials
397 132nd of 735 higher than 604 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
- NCT05365581 · 398 participants · Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI